Ana Buj-Bello

Ana Buj-Bello

Genethon, 91000, Evry, France

Affiliated withGenethon, 91000, Evry, FranceUniversité Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare research unit UMR_S951, 91000, Evry, France

Research Area

Biography

Ana Buj Bello is research director at INSERM and head of the Neuromuscular Diseases and GeneTherapy team at Genethon, France. She received her degree in Medicine and Surgery from the University of Lleida, Spain, and a PhD in Neurosciences from the University of St Andrews, UK. She also obtained a diploma in Myology from the University of Pierre et Marie Curie, France. Having done a post-doctorate at the « Institut de Génétique et Biologie Moléculaire et Cellulaire » (IGBMC), France, she joined the INSERM in 2004 and has worked at Genethon since 2009. Her research activities focus on developing AAV-based gene therapies for neuromuscular disorders, in particular congenital myopathies, with a major interest in clinical translation. Her pioneering work on gene replacement therapy for myotubular myopathy has led to the initiation of a clinical trial in patients.

JoVE Journal Publications

ArticleTotal : 1
Year
Characterization of Neuromuscular Junctions in Mice by Combined Confocal and Super-Resolution Microscopy
Publication title

Cited by 2

2021

Other Publications

Article
Year
Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs.

Molecular therapy : the journal of the American Society of Gene Therapy| PubMed ID: 28237839

2017
Genome Editing of Expanded CTG Repeats within the Human DMPK Gene Reduces Nuclear RNA Foci in the Muscle of DM1 Mice.

Molecular therapy : the journal of the American Society of Gene Therapy| PubMed ID: 31253581

2019